Volume 80, Issue 1, Pages (July 2011)

Slides:



Advertisements
Similar presentations
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Advertisements

Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
Improved prognosis of diabetic nephropathy in type 1 diabetes
Chronic Kidney Disease in Diabetes
Melody Sherwood, Peter A McCullough  The Lancet Global Health 
Chapter 1: CKD in the General Population
Volume 80, Issue 1, Pages (July 2011)
Copyright © 2012 American Medical Association. All rights reserved.
Volume 67, Issue 6, Pages (June 2005)
Chapter 1: Definition and classification of CKD
Frederik Persson, Peter Rossing  Kidney International Supplements 
Simon Sawhney, Simon D. Fraser  Advances in Chronic Kidney Disease 
Estimated Glomerular Filtration Rate From a Panel of Filtration Markers—Hope for Increased Accuracy Beyond Measured Glomerular Filtration Rate?  Lesley.
Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and.
Chapter 1: CKD in the General Population
Section 2: AKI Definition
Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline  Krista L. Lentine, MD, PhD, Andrew S. Levey, MD,
Kidney International Supplements 
Volume 92, Issue 1, Pages (July 2017)
From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria  Paul E. De Jong, Barry M. Brenner  Kidney International 
A Decade After the KDOQI CKD Guidelines
Update on acute kidney injury after cardiac surgery
Volume 79, Issue 12, Pages (June 2011)
Volume 92, Issue 2, Pages (August 2017)
Simon Sawhney, Simon D. Fraser  Advances in Chronic Kidney Disease 
Volume 80, Issue 9, (November 2011)
Corrections to "Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated.
Volume 80, Issue 1, Pages (July 2011)
Melody Sherwood, Peter A McCullough  The Lancet Global Health 
John P. Middleton, Patrick H. Pun  Kidney International 
GFR Estimation: From Physiology to Public Health
Volume 80, Issue 2, Pages (July 2011)
Volume 66, Issue 1, Pages (July 2004)
Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundation–Kidney Early Evaluation Program (KEEP) 2012.
Chapter 5: Referral to specialists and models of care
Volume 86, Issue 4, Pages (October 2014)
Your Kidneys May Outlive You
Volume 72, Issue 10, Pages (November 2007)
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration 
Comprehensive Public Health Strategies for Preventing the Development, Progression, and Complications of CKD: Report of an Expert Panel Convened by the.
Meeting the challenges of the new K/DOQI guidelines
Acute Kidney Injury and CKD: Chicken or Egg?
Utility and Validity of Estimated GFR–Based Surrogate Time-to-Event End Points in CKD: A Simulation Study  Tom Greene, PhD, Chia-Chen Teng, MS, Lesley.
Volume 92, Issue 1, Pages (July 2017)
Volume 79, Issue 12, Pages (June 2011)
Volume 75, Issue 10, Pages (May 2009)
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Volume 91, Issue 1, Pages (January 2017)
American Journal of Kidney Diseases
U-shaped effect of eGFR and mortality
Beef Tea, Vitality, Creatinine, and the Estimated GFR
Volume 65, Issue 3, Pages (March 2004)
Volume 90, Issue 5, Pages (November 2016)
Volume 76, Issue 3, Pages (August 2009)
Evidence and Outcomes in CKD
Within-Person Variability in Kidney Measures
Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske 
Methods for guideline development
Improved prognosis of diabetic nephropathy in type 1 diabetes
Lesley A. Stevens, MD, MS, Josef Coresh, MD, PhD, Andrew S. Levey, MD 
Volume 80, Issue 12, Pages (December 2011)
Volume 72, Issue 3, Pages (August 2007)
Volume 60, Issue 1, Pages (July 2001)
Volume 76, Issue 6, Pages (September 2009)
Blood lead and chronic kidney disease in the general United States population: Results from NHANES III  Paul Muntner, Jiang He, Suma Vupputuri, Josef.
Introduction: The case for updating and context
Conceptual model of the course of chronic kidney disease (CKD).
Volume 78, Issue 5, Pages (September 2010)
Jacob J.E. Koopman, MD, PhD  American Journal of Kidney Diseases 
Presentation transcript:

Volume 80, Issue 1, Pages 17-28 (July 2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report  Andrew S. Levey, Paul E. de Jong, Josef Coresh, Meguid E.l. Nahas, Brad C. Astor, Kunihiro Matsushita, Ron T. Gansevoort, Bertram L. Kasiske, Kai-Uwe Eckardt  Kidney International  Volume 80, Issue 1, Pages 17-28 (July 2011) DOI: 10.1038/ki.2010.483 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 Conceptual model (updated). This diagram presents the continuum of development, progression, and complications of chronic kidney disease.1,2 Green circles represent stages of chronic kidney disease; aqua circles represent potential antecedents, lavender circles represent consequences, and thick arrows between ellipses represent risk factors associated with the development, progression, and remission of chronic kidney disease. ‘Complications’ refers to all complications of chronic kidney disease and interventions for its treatment and prevention, including complications of decreased glomerular filtration rate (GFR) and cardiovascular disease. Kidney International 2011 80, 17-28DOI: (10.1038/ki.2010.483) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 2 Percentage of US population by estimated glomerular filtration rate (eGFR) and albuminuria category using the definition and classification of chronic kidney disease (Kidney Disease Outcomes Quality Initiative (KDOQI) 2002 and Kidney Disease: Improving Global Outcomes (KDIGO) 2004) and prevalence estimates from National Health and Nutrition Examinations Survey III (NHANES III; 1988–1994) based on Modification of Diet in Renal Disease (MDRD) Study eGFR and standardized serum creatinine. Albuminuria ascertained by single measurement of albumin-to-creatinine ratio. Values in cells do not total to 100% because of rounding. Kidney International 2011 80, 17-28DOI: (10.1038/ki.2010.483) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 3 Flow diagram of cohorts.*Three cohorts (AKDN, AusDiab, Grampian) were divided into two subcohorts for meta-analysis according to ascertainment of albuminuria with variable overlap between subcohorts. Note: The study name expansions are provided in the Appendix. Kidney International 2011 80, 17-28DOI: (10.1038/ki.2010.483) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 4 Summary of continuous meta-analysis (adjusted relative risk (RR)) for general population cohorts with albumin-to-creatinine ratio (ACR). Mortality is reported for general population cohorts assessing albuminuria as urine ACR. Kidney outcomes are reported for general population cohorts assessing albuminuria as either urine ACR or dipstick. Estimated glomerular filtration rate (eGFR) is expressed as a continuous variable. The three lines represent urine ACR of <30mg/g or dipstick negative and trace (blue), urine ACR 30–299mg/g or dipstick 1+ positive (green), and urine ACR ≥300mg/g or dipstick ≥2+ positive (red). All results are adjusted for covariates and compared with reference point of eGFR of 95ml/min per 1.73m2 and ACR of <30mg/g or dipstick negative (diamond). Each point represents the pooled relative risk from a meta-analysis. Solid circles indicate statistical significance compared with the reference point (P<0.05); triangles indicate non-significance. Red arrows indicate eGFR of 60ml/min per 1.73m2, threshold value of eGFR for the current definition of chronic kidney disease (CKD). HR, hazards ratio; OR, odds ratio. Kidney International 2011 80, 17-28DOI: (10.1038/ki.2010.483) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 5 Summary of categorical meta-analysis (adjusted relative risk (RR)) for general population cohorts with albumin-to-creatinine ratio (ACR). Mortality is reported for general population cohorts assessing albuminuria as urine ACR. Kidney outcomes are reported for general population cohorts assessing albuminuria as either urine ACR or dipstick. Estimated glomerular filtration rate (eGFR) and albuminuria are expressed as categorical variables. All results are adjusted for covariates and compared with the reference cell (Ref). Each cell represents a pooled relative risk from a meta-analysis; bold numbers indicate statistical significance at P<0.05. Incidence rates per 1000 person-years for the reference cells are 7.0 for all-cause mortality, 4.5 for cardiovascular disease mortality, 0.04 for kidney failure, 0.98 for acute kidney injury (AKI), and 2.02 for kidney disease progression. Absolute risk can be computed by multiplying the relative risks in each cell by the incidence rate in the reference cell. Colors reflect the ranking of adjusted relative risk. The point estimates for each cell were ranked from 1 to 28 (the lowest RR having rank number 1, and the highest number 28). The categories with rank numbers 1–8 are green, rank numbers 9–14 are yellow, the rank numbers 15–21 are orange, and the rank numbers 22–28 are colored red. (For the outcome of kidney disease progression, two cells with RR <1.0 are also green, leaving fewer cells as orange.) Kidney International 2011 80, 17-28DOI: (10.1038/ki.2010.483) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 6 Composite Ranking for Relative Risks by glomerular filtration rate (GFR) and Albuminuria (Kidney Disease: Improving Global Outcomes (KDIGO) 2009). As in Figure 5, colors reflect the ranking of adjusted relative risk. The ranks assigned in Figure 5 were averaged across all five outcomes for the 28 GFR and albuminuria categories. The categories with mean rank numbers 1–8 are green, mean rank numbers 9–14 are yellow, mean rank numbers 15–21 are orange, and mean rank numbers 22–28 are red. Color for twelve additional cells with diagonal hash marks is extrapolated based on results from the meta-analysis of chronic kidney disease cohorts. The highest level of albuminuria is termed ‘nephrotic’ to correspond with nephrotic range albuminuria and is expressed here as ≥2000mg/g. Column and row labels are combined to be consistent with the number of estimated GFR (eGFR) and albuminuria stages agreed on at the conference. Kidney International 2011 80, 17-28DOI: (10.1038/ki.2010.483) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 7 Percentage of US population by estimated glomerular filtration rate (eGFR) and albuminuria category using: definition and classification of chronic kidney disease (Kidney Disease: Improving Global Outcomes (KDIGO) 2009) and prevalence estimates from National Health and Nutrition Examinations Survey III (NHANES III; 1988–1994) based on Modification of Diet in Renal Disease (MDRD) Study eGFR and standardized serum creatinine. Albuminuria ascertained by single measurement of albumin-to-creatinine ratio. Values in cells do not total to values in margins because of rounding. Category of very high albuminuria includes nephrotic range. Kidney International 2011 80, 17-28DOI: (10.1038/ki.2010.483) Copyright © 2011 International Society of Nephrology Terms and Conditions